^
    3years
    Sustained response to brigatinib in a patient with refractory metastatic pheochromocytoma harboring R1192P anaplastic lymphoma kinase mutation: a case report from the Austrian Group Medical Tumor Therapy next-generation sequencing registry and discussion of the literature. (PubMed, ESMO Open)
    Therapy with the ALK inhibitor (ALKi) brigatinib led to dramatic and durable disease remission, despite previous disease progression on the ALKi alectinib. This case underscores the potential clinical use of molecular profiling in rare diseases with limited treatment options and suggests that the ALK-R1192P point mutation might predict sensitivity to brigatinib.
    Clinical • Review • Journal • Next-generation sequencing
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK mutation • ALK R1192P
    |
    Alecensa (alectinib) • Alunbrig (brigatinib)